Brooks Laboratories Limited (BROOKS.BO)
INR 132.4
(7.55%)
INR 132.4
(7.55%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -195.91 Million INR | 36.91% |
| 2022 | -310.54 Million INR | -60.8% |
| 2021 | -193.12 Million INR | 0.33% |
| 2020 | -193.75 Million INR | 20.51% |
| 2019 | -243.76 Million INR | -64.64% |
| 2018 | -148.05 Million INR | -7.19% |
| 2017 | -138.12 Million INR | -928.65% |
| 2016 | 16.66 Million INR | -84.32% |
| 2015 | 106.33 Million INR | 12.32% |
| 2014 | 94.67 Million INR | 30.77% |
| 2013 | 72.39 Million INR | 1.34% |
| 2012 | 71.43 Million INR | -19.15% |
| 2011 | 88.35 Million INR | 28.28% |
| 2010 | 68.88 Million INR | 33.18% |
| 2009 | 51.71 Million INR | 74.49% |
| 2008 | 29.64 Million INR | -8.15% |
| 2007 | 32.27 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -24.13 Million INR | 74.88% |
| 2023 Q1 | -44.7 Million INR | 69.07% |
| 2023 Q2 | -16.37 Million INR | 63.38% |
| 2023 Q3 | -38.78 Million INR | -136.92% |
| 2023 Q4 | -96.06 Million INR | -147.67% |
| 2023 FY | -195.91 Million INR | 36.91% |
| 2022 Q1 | -69 Million INR | -2.56% |
| 2022 Q2 | -46.82 Million INR | 32.15% |
| 2022 Q3 | -50.19 Million INR | -7.2% |
| 2022 Q4 | -144.52 Million INR | -187.96% |
| 2022 FY | -310.54 Million INR | -60.8% |
| 2021 FY | -193.12 Million INR | 0.33% |
| 2021 Q2 | -48.3 Million INR | -322.77% |
| 2021 Q4 | -67.28 Million INR | -1.77% |
| 2021 Q3 | -66.11 Million INR | -36.86% |
| 2021 Q1 | -11.42 Million INR | 93.39% |
| 2020 FY | -193.75 Million INR | 20.51% |
| 2020 Q1 | -28.87 Million INR | 81.91% |
| 2020 Q2 | 33.65 Million INR | 216.57% |
| 2020 Q3 | -25.55 Million INR | -175.92% |
| 2020 Q4 | -172.98 Million INR | -577.06% |
| 2019 Q4 | -159.58 Million INR | -468.6% |
| 2019 Q2 | -18.77 Million INR | 49.73% |
| 2019 Q3 | -28.06 Million INR | -49.53% |
| 2019 FY | -243.76 Million INR | -64.64% |
| 2019 Q1 | -37.34 Million INR | 46.23% |
| 2018 Q3 | -21.46 Million INR | -7.25% |
| 2018 FY | -148.05 Million INR | -7.19% |
| 2018 Q2 | -20 Million INR | 46.12% |
| 2018 Q1 | -37.13 Million INR | -64.16% |
| 2018 Q4 | -69.44 Million INR | -223.61% |
| 2017 Q3 | -26.22 Million INR | 13.21% |
| 2017 Q1 | -58.76 Million INR | -397.82% |
| 2017 FY | -138.12 Million INR | -928.65% |
| 2017 Q4 | -22.62 Million INR | 13.74% |
| 2017 Q2 | -30.21 Million INR | 48.58% |
| 2016 FY | 16.66 Million INR | -84.32% |
| 2016 Q4 | -11.8 Million INR | -346.45% |
| 2016 Q3 | 4.79 Million INR | -34.81% |
| 2016 Q1 | 16.33 Million INR | -64.66% |
| 2016 Q2 | 7.34 Million INR | -55.03% |
| 2015 FY | 106.33 Million INR | 12.32% |
| 2015 Q3 | 27.94 Million INR | 64.23% |
| 2015 Q2 | 17.01 Million INR | 12.41% |
| 2015 Q1 | 15.13 Million INR | -35.37% |
| 2015 Q4 | 46.23 Million INR | 65.44% |
| 2014 Q1 | 15.35 Million INR | -23.23% |
| 2014 Q4 | 23.42 Million INR | 31.02% |
| 2014 FY | 94.67 Million INR | 30.77% |
| 2014 Q2 | 38.02 Million INR | 147.71% |
| 2014 Q3 | 17.87 Million INR | -52.98% |
| 2013 Q2 | 18.99 Million INR | -0.4% |
| 2013 Q4 | 19.99 Million INR | 41.26% |
| 2013 FY | 72.39 Million INR | 1.34% |
| 2013 Q3 | 14.15 Million INR | -25.48% |
| 2013 Q1 | 19.07 Million INR | 684.71% |
| 2012 Q3 | 29.8 Million INR | 2.41% |
| 2012 Q2 | 29.1 Million INR | 84.18% |
| 2012 Q4 | -3.26 Million INR | -110.94% |
| 2012 Q1 | 15.8 Million INR | -18.38% |
| 2012 FY | 71.43 Million INR | -19.15% |
| 2011 Q2 | 25.5 Million INR | 0.0% |
| 2011 Q4 | 19.35 Million INR | -34.38% |
| 2011 FY | 88.35 Million INR | 28.28% |
| 2011 Q3 | 29.5 Million INR | 15.69% |
| 2010 FY | 68.88 Million INR | 33.18% |
| 2009 FY | 51.71 Million INR | 74.49% |
| 2008 FY | 29.64 Million INR | -8.15% |
| 2007 FY | 32.27 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 100.205% |
| NATCO Pharma Limited | 13.88 Billion INR | 101.411% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 106.525% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 177.395% |
| Achyut Healthcare Limited | 5.73 Million INR | 3517.987% |
| Ajanta Pharma Limited | 8.16 Billion INR | 102.4% |
| Alkem Laboratories Limited | 17.95 Billion INR | 101.091% |
| Alpa Laboratories Limited | 167.76 Million INR | 216.782% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 103.181% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 112.13% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 100.617% |
| Bajaj HealthCare Limited | -837.93 Million INR | 76.619% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 125.965% |
| Divi's Laboratories Limited | 16 Billion INR | 101.224% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 100.352% |
| Eris Lifesciences Limited | 3.91 Billion INR | 104.998% |
| FDC Limited | 3.05 Billion INR | 106.419% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 98.695% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 104.161% |
| Granules India Limited | 4.05 Billion INR | 104.834% |
| Gufic Biosciences Limited | 861.35 Million INR | 122.745% |
| Hester Biosciences Limited | 188.89 Million INR | 203.721% |
| Indoco Remedies Limited | 984.6 Million INR | 119.898% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 104.654% |
| Ipca Laboratories Limited | 5.47 Billion INR | 103.579% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 187.219% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 0.692% |
| Lasa Supergenerics Limited | -217.3 Million INR | 9.842% |
| Laurus Labs Limited | 1.6 Billion INR | 112.203% |
| Lupin Limited | 19.14 Billion INR | 101.023% |
| Mankind Pharma Limited | 19.12 Billion INR | 101.024% |
| Medicamen Biotech Limited | 109.31 Million INR | 279.232% |
| Medico Remedies Limited | 82.9 Million INR | 336.306% |
| Megasoft Limited | -127.46 Million INR | -53.703% |
| Piramal Pharma Limited | 178.2 Million INR | 209.943% |
| RPG Life Sciences Limited | 876.6 Million INR | 122.35% |
| Sigachi Industries Limited | 571.8 Million INR | 134.263% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 94.94% |
| Unichem Laboratories Limited | -704.74 Million INR | 72.2% |
| Wanbury Limited | 559.56 Million INR | 135.013% |
| Windlas Biotech Limited | 581.87 Million INR | 133.671% |
| ZIM Laboratories Limited | 172.46 Million INR | 213.6% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 100.508% |
| Procter & Gamble Health Limited | 2 Billion INR | 109.748% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 143.564% |
| Bal Pharma Limited | 73.92 Million INR | 365.035% |
| Strides Pharma Science Limited | -706.14 Million INR | 72.255% |
| Venus Remedies Limited | 284.9 Million INR | 168.766% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 109.033% |
| Nectar Lifesciences Limited | 49.95 Million INR | 492.23% |
| Shilpa Medicare Limited | 318.74 Million INR | 161.466% |
| Aarti Drugs Limited | 1.71 Billion INR | 111.429% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 114.574% |
| Suven Life Sciences Limited | -1.05 Billion INR | 81.355% |
| Ind-Swift Limited | 142.31 Million INR | 237.668% |
| Valiant Laboratories Limited | 3.19 Million INR | 6230.131% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 103.545% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 96.547% |
| Themis Medicare Limited | 435.23 Million INR | 145.014% |
| Hikal Limited | 696.02 Million INR | 128.148% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 101.183% |
| Sequent Scientific Limited | -358.69 Million INR | 45.379% |
| Novartis India Limited | 851.9 Million INR | 122.998% |
| Wockhardt Limited | -4.63 Billion INR | 95.768% |
| Jubilant Pharmova Limited | 771 Million INR | 125.411% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | 2862.535% |
| Neuland Laboratories Limited | 3 Billion INR | 106.529% |
| Morepen Laboratories Limited | 961.59 Million INR | 120.374% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 234.178% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | -115.967% |